- Home
- PRME vs EYPT Comparison
PRME vs EYPT Comparison
Compare PRME & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- EYPT
- Stock Information
- Founded
- PRME 2019
- EYPT 1987
- Country
- PRME United States
- EYPT United States
- Employees
- PRME N/A
- EYPT N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PRME Health Care
- EYPT Industrials
- Exchange
- PRME Nasdaq
- EYPT Nasdaq
- Market Cap
- PRME 693.5M
- EYPT 967.4M
- IPO Year
- PRME 2022
- EYPT 2005
- Fundamental
- Price
- PRME $4.54
- EYPT $11.73
- Analyst Decision
- PRME Buy
- EYPT Strong Buy
- Analyst Count
- PRME 6
- EYPT 5
- Target Price
- PRME $8.88
- EYPT $27.40
- AVG Volume (30 Days)
- PRME 4.3M
- EYPT 1.4M
- Earning Date
- PRME 11-07-2025
- EYPT 11-05-2025
- Dividend Yield
- PRME N/A
- EYPT N/A
- EPS Growth
- PRME N/A
- EYPT N/A
- EPS
- PRME N/A
- EYPT N/A
- Revenue
- PRME $4,961,000.00
- EYPT $51,898,000.00
- Revenue This Year
- PRME $179.58
- EYPT N/A
- Revenue Next Year
- PRME N/A
- EYPT N/A
- P/E Ratio
- PRME N/A
- EYPT N/A
- Revenue Growth
- PRME 739.42
- EYPT 2.99
- 52 Week Low
- PRME $1.11
- EYPT $3.91
- 52 Week High
- PRME $6.94
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- PRME 40.95
- EYPT 42.55
- Support Level
- PRME $4.93
- EYPT $11.15
- Resistance Level
- PRME $5.55
- EYPT $12.21
- Average True Range (ATR)
- PRME 0.57
- EYPT 0.71
- MACD
- PRME -0.21
- EYPT -0.10
- Stochastic Oscillator
- PRME 3.21
- EYPT 19.60
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.